第1章 目次

第2章 イントロダクション

第3章 疾患の概要

第4章 疾病の管理

症状と治療の概要

第5章 競合評価

概要

第6章 機会とアンメットニーズ

概要

より効果的な薬物療法

より良好な副作用プロファイル

抗うつ効果の迅速な発現

個別化医療のアプローチ

第7章 パイプライン分析

概要

臨床開発中の有望な薬剤

第8章 GLYX-13

概要

効能

安全性

投与と処方

臨床および市場における潜在的な位置づけ

SWOT分析

予測

第9章 付録

図表

目次

Product Code: GDHC429DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

GLYX-13 is being developed by Naurex as an adjunctive therapy for MDD in patients with an inadequate response to antidepressants. The exact MOA of GLYX-13 is not fully understood, but it is hypothesized that it exerts its antidepressant effects by enhancing synaptic plasticity (Naurex, press release, December 12, 2013). GLYX-13 is being developed for IV administration and there is evidence to suggest that the NMDA receptor ligands can demonstrate rapid antidepressant effects (Popp et al., 2013).

Scope

Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on GLYX-13 including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for GLYX-13 for the top eight countries from 2013 to 2023.